| Literature DB >> 21991356 |
Rabia Hussain1, Ambreen Ansari, Najeeha Talat, Zahra Hasan, Ghaffar Dawood.
Abstract
Among the known biomarkers, chemokines, secreted by activated macrophages and T cells, attract groups of immune cells to the site of infection and may determine the clinical outcome. Association studies of CCL-2/MCP-1 -2518 A/G functional SNP linked to high and low phenotypes with tuberculosis disease susceptibility have shown conflicting results in tuberculosis. Some of these differences could be due the variability of latent infection and recent exposure in the control groups. We have therefore carried out a detailed analysis of CCL-2 genotype SNP -2518 (A/G transition) with plasma CCL-2 levels and related these levels to tuberculin skin test positivity in asymptomatic community controls with no known exposure to tuberculosis and in recently exposed household contacts of pulmonary tuberculosis patients. TST positivity was linked to higher concentrations of plasma CCL2 (Mann Whitney U test; p = 0.004) and was more marked when the G allele was present in TST+ asymptomatic controls (A/G; p = 0.01). Recent exposure also had a significant effect on CCL-2 levels and was linked to the G allele (p = 0.007). Therefore association studies for susceptibility or protection from disease should take into consideration the PPD status as well as recent exposure of the controls group used for comparison. Our results also suggest a role for CCL-2 in maintaining the integrity of granuloma in asymptomatic individuals with latent infection in high TB burden settings. Therefore additional studies into the role of CCL-2 in disease reactivation and progression are warranted.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21991356 PMCID: PMC3186769 DOI: 10.1371/journal.pone.0025803
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the study group.
| Group ID | N | Age ± SD | Sex ratio M/F (ratio) |
|
| TBNA | 196 | 27.91±12.58 | 90/106 (0.85) | 117/184 (61%) |
| EC | 86 | 29.12±7.63 | 33/53 (0.62) | 34/74 (46%) |
| HC | 110 | 26.96±15.35 | 57/53 (1.08) | 83/110 (75%) |
Note: TBNA = TB not affected:
TBNA Subsets = EC = Community Controls, HC exposed household contacts.
*Cut off for TST positivity ≥10 mm of indurations.
Figure 1CCL-2 genotype-phenotype relationship in healthy asymptomatic control groups.
PCR and sequencing analyses was carried out to determine the CCL-2 (SNP -2815) (see Figure S1) and BD FACS array was carried out to determine CCL-2 protein in plasma samples. The number in each genotype is indicated in the brackets. Kruskall-Wallis (KW) analysis was applied to determine significant differences across groups.
CCL-2 levels in plasma in relation to infection and disease in tuberculosis.
| Groups (N) | N | Mean (pg/ml) | ±SE | p = |
| TBNA | 157 | 59.8 | 4.5 | |
| TBNA (+) | 91 | 71.6 | 6.2 | |
| TBNA (−) | 49 | 47.4 | 6.3 | 0.0040 |
| EC | 65 | 45 | 9.2 | |
| HC | 92 | 70.1 | 3.7 | 0.052 |
| EC (+) | 23 | 67 | 21.1 | |
| HC (+) | 68 | 73.2 | 4.4 | 0.3 |
Note: TBNA = TB not affected:
TBNA Subsets = EC = Community Controls; HC exposed household contacts.
(+) = TST positive (> = 10 mm indurations); (−) = TST negative (<10 mm indurations).
Significance of differences was assessed by applying student t tests (1 tail, type 3).
A p value of <0.05 was considered significant.
CCL-2 (-2518 G/A) genotype and allele analysis.
| CCL-2 – 2518 | TBNA (+) | TBNA (−) | EC | HC | EC(+) | HC(+) |
| SNP Genotype |
|
|
|
|
|
|
| N | 117 | 67 | 86 | 110 | 34 | 82 |
| AA | 41.88 | 49.30 | 45.35 | 43.64 | 44.12 | 41.46 |
| AG | 43.59 | 44.80 | 51.16 | 39.03 | 50 | 40.2 |
| GG | 14.53 | 15.97 | 3.49 | 17.27 | 5.88 | 18.29 |
| X2 | 2.39 |
| 2.89 | |||
| Corrected | Vs TBNA+ |
| Vs EC+ | |||
| p = | .122 |
| 0.089 | |||
| allele | ||||||
| A | 63.675 | 71.6 | 70.93 | 63.18 | 69.12 | 62.59 |
| G | 36.325 | 28.4 | 29.07 | 36.82 | 30.88 | 38.41 |
| X2 | 2.42 | 2.6 | 1.18 | |||
| p = | .21 | .107 | .277 | |||
| OR | .69 | .7 | .72 | |||
| 95% CI | 0.44–1.1 | 0.46–1.08 | 0.39–1.31 | |||
| HWE p = | .876 | .615 | .957 | .515 | .876 | .615 |
Note: TBNA = TB not affected:
TBNA Subsets = EC = Community Controls, HC exposed household contacts.
TST positive = (+); TST negative = (−). TST positivity cut off = ≥10 mm indurations.
HWE = Hardy Weinberg Equilibrium. P<0.05 is considered significant.
Figure 2CCL-2 genotype-phenotype relationship in the presence (TST+) or absence (TST-) of latency in asymptomatic healthy controls.
TST+ (cut off > = 10 mm diameter indurations). The number in each panel is indicated in the boxes. Significant differences were determined by Mann Whitney U analysis between different genotytpes. A p value <0.05 was considered significant. Genotypes were unavailable on 2 donors and therefore not included. All other parameters are same as in table 2 and 3.
Figure 3CCL-2 genotype-phenotype relationship in the presence (TST+) or absence (TST-) of latency in recently exposed household contacts (Panel A) and healthy community controls (Panel B).
The number in each group is indicated in the boxes. Significant differences were determined by Mann Whitney U analysis between different genotytpes. A p value <0.05 was considered significant.
Receiver Operator analysis of CCL2 (pg/ml) in Healthy Asymptomatic Community Controls in relation to Tuberculin Skin test Status (TST).
| Groups | N | AUROC | p = | CI |
| EC− Vs HC + | 27 Vs 80 | .736 | 0.0003 | 0.605–.867 |
| EC− VS HC | 27 Vs 104 | .694 | 0.002 | .571–.817 |
| EC+ Vs HC+ | 24 Vs 80 | .658 | 0.019 | .172–.512 |
EC = Community Controls; HC exposed household contacts. + = TST positive (> = 10 mm indurations);
− = TST negative (<10 mm indurations).